126 related articles for article (PubMed ID: 16904111)
1. Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor.
Mandic R; Rodgarkia-Dara CJ; Zhu L; Folz BJ; Bette M; Weihe E; Neubauer A; Werner JA
FEBS Lett; 2006 Sep; 580(20):4793-800. PubMed ID: 16904111
[TBL] [Abstract][Full Text] [Related]
2. EGFR codon 497 polymorphism - implications for receptor sensitivity to inhibitors in HNSCC cell lines.
Krohn V; Wiegand S; Werner JA; Mandic R
Anticancer Res; 2011 Jan; 31(1):59-65. PubMed ID: 21273581
[TBL] [Abstract][Full Text] [Related]
3. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
Jedlinski A; Ansell A; Johansson AC; Roberg K
J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor alpha stimulation of mucosal tissue cultures from head and neck squamous cell carcinoma patients increases chemoresistance to cisplatin.
Baumeister P; Reiter M; Schwenk-Zieger S; Harréus U
Chemotherapy; 2010; 56(4):268-74. PubMed ID: 20693797
[TBL] [Abstract][Full Text] [Related]
5. Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation.
Gschwind A; Prenzel N; Ullrich A
Cancer Res; 2002 Nov; 62(21):6329-36. PubMed ID: 12414665
[TBL] [Abstract][Full Text] [Related]
6. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Johnson FM; Saigal B; Donato NJ
J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Shintani S; Kiyota A; Mihara M; Sumida T; Kayahara H; Nakashiro K; Hamakawa H
Am J Clin Oncol; 2003 Oct; 26(5):e150-6. PubMed ID: 14528090
[TBL] [Abstract][Full Text] [Related]
8. Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells.
Takaoka S; Iwase M; Uchida M; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M; Shintani S
Int J Oncol; 2007 Jun; 30(6):1469-76. PubMed ID: 17487368
[TBL] [Abstract][Full Text] [Related]
9. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
10. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor.
Mandic R; Rodgarkia-Dara CJ; Krohn V; Wiegand S; Grénman R; Werner JA
Anticancer Res; 2009 Apr; 29(4):1181-7. PubMed ID: 19414362
[TBL] [Abstract][Full Text] [Related]
12. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells.
Zhang Q; Thomas SM; Xi S; Smithgall TE; Siegfried JM; Kamens J; Gooding WE; Grandis JR
Cancer Res; 2004 Sep; 64(17):6166-73. PubMed ID: 15342401
[TBL] [Abstract][Full Text] [Related]
13. Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines.
Kondo N; Tsukuda M; Sakakibara A; Takahashi H; Hyakusoku H; Komatsu M; Niho T; Nakazaki K; Toth G
Int J Oncol; 2012 Jun; 40(6):1805-12. PubMed ID: 22344385
[TBL] [Abstract][Full Text] [Related]
14. Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor.
Lui VW; Thomas SM; Zhang Q; Wentzel AL; Siegfried JM; Li JY; Grandis JR
Oncogene; 2003 Sep; 22(40):6183-93. PubMed ID: 13679857
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma.
Thomas SM; Coppelli FM; Wells A; Gooding WE; Song J; Kassis J; Drenning SD; Grandis JR
Cancer Res; 2003 Sep; 63(17):5629-35. PubMed ID: 14500405
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling.
Hasselbalch B; Lassen U; Poulsen HS; Stockhausen MT
Cancer Invest; 2010 Oct; 28(8):775-87. PubMed ID: 20504227
[TBL] [Abstract][Full Text] [Related]
17. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.
Johns TG; Luwor RB; Murone C; Walker F; Weinstock J; Vitali AA; Perera RM; Jungbluth AA; Stockert E; Old LJ; Nice EC; Burgess AW; Scott AM
Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15871-6. PubMed ID: 14676326
[TBL] [Abstract][Full Text] [Related]
18. Activation by tyrosine phosphorylation as a prerequisite for protein kinase Cζ to mediate epidermal growth factor receptor signaling to ERK.
Valkova C; Mertens C; Weisheit S; Imhof D; Liebmann C
Mol Cancer Res; 2010 May; 8(5):783-97. PubMed ID: 20407013
[TBL] [Abstract][Full Text] [Related]
19. Aberrant kinase signaling: lessons from head and neck cancer.
Nelson EG; Grandis JR
Future Oncol; 2007 Jun; 3(3):353-61. PubMed ID: 17547530
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of combined treatment with cetuximab (erbitux) and radiation therapy in patients with head and neck cancer.
Koukourakis G; Kouloulias V; Koukourakis M; Kouvaris J; Zacharias G; Gouliamos A
J BUON; 2009; 14(1):19-25. PubMed ID: 19373942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
